Papillomavirus pseudoviruses for detection and therapy of tumors
AssigneeThe United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of Health
InventorsJeff Roberts, Douglas R. Lowy, John T. Schiller
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP)
Claims33
A method of detecting the presence of cancer cells bound to a papilloma pseudovirus or a papilloma VLP comprising:
- identifying a subject having or suspected of having cancer cells;
- administering to said subject a detectable amount of a papilloma pseudovirus or a papilloma VLP that comprises a detectable label;
- and
- detecting the presence of cancer cells bound to said papilloma pseudovirus or said papilloma VLP that comprises a detectable label.
(canceled)
(canceled)
A method for evaluating a cancer therapy comprising:
- identifying a subject with a cancer;
- providing said subject a cancer therapy;
- administering to said subject a detectable amount of a papilloma pseudovirus or papilloma VLP that comprises a detectable label;
- and
- determining the presence or amount of said pseudovirus or said VLP bound to cancer cells in said subject, before a treatment with said cancer therapy and during or after a period of said treatment.
(canceled)
(canceled)
A method of inhibiting the proliferation of cancer cells and/or killing cancer cells without inhibiting proliferation and/or killing of normal cells comprising:
- identifying a subject with a cancer;
- and
- administering to said identified subject a composition that comprises a therapeutic agent formulated with a papilloma pseudovirus or a papilloma VLP.
A kit comprising a papilloma pseudovirus or a papilloma VLP, a pharmaceutical carrier, and instructions for using the kit components.
A method of detecting the presence of cervical cancer in a subject, comprising:
- providing to said subject a composition comprising a papilloma VLP coupled to or containing a label;
- removing unbound VLPs that comprise said label;
- and
- detecting the presence of cancer cells bound to said VLP that comprises said label.
(canceled)
(canceled)
A nucleic acid comprising an oligo T domain of at least 10 and less than or equal to 200 consecutive T residues.
Dependencies are inferred from the claim text.